<!DOCTYPE html>
<html lang="en-us">
<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="theme" content="hugo-academic">
  <meta name="generator" content="Hugo 0.42.1" />
  <meta name="author" content="Ming Tang">

  
  
  
  
    
      
    
  
  <meta name="description" content="Immune checkpoint therapies exhibit impressive efficacy in some patients with melanoma or lung cancer, but the lack of response in most cases presses the question of how general efficacy can be improved. In addressing this question, we generated a preclinical tumor model to study anti-PD-1 resistance by in vivo passaging of Kras-mutated, p53-deficient murine lung cancer cells (p53R172HDg/Ã¾K-rasLA1/Ã¾) in a syngeneic host exposed to repetitive dosing with anti-mouse PD-1 antibodies. PD-L1 (CD274) expression did not differ between the resistant and parental tumor cells. However, the expression of important molecules in the antigen presentation pathway, including MHC class I and II, as well as b2-microglobulin, were significantly downregulated in the anti-PD-1â€“resistant tumors compared with parental tumors. Resistant tumors also contained fewer CD8Ã¾ (CD8a) and CD4Ã¾ tumor-infiltrating lymphocytes and reduced production of IFNg. Localized radiotherapy induced IFNb production, thereby elevating MHC class I expression on both parental and resistant tumor cells and restoring the responsiveness of resistant tumors to anti-PD-1 therapy. Conversely, blockade of type I IFN signaling abolished the effect of radiosensitization in this setting. Collectively, these results identify a mechanism of PD-1 resistance and demonstrate that adjuvant radiotherapy can overcome resistance. These findings have immediate clinical implications for extending the efficacy of anti-PD-1 immune checkpoint therapy in patients.">

  
  <link rel="alternate" hreflang="en-us" href="/publication/2017-02-15-ifn-signaling-tumor-pd1-resistance/">

  


  

  
  
  <meta name="theme-color" content="#328cc1">
  
  
  
  
    
  
  
    
    
      
        <link rel="stylesheet" href="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/styles/github.min.css">
      
    
  
  
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.3.7/css/bootstrap.min.css" integrity="sha512-6MXa8B6uaO18Hid6blRMetEIoPqHf7Ux1tnyIQdpt9qI5OACx7C+O3IVTr98vwGnlcg0LOLa02i9Y1HpVhlfiw==" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.7.0/css/font-awesome.min.css" integrity="sha512-SfTiTlX6kk+qitfevl/7LibUOeJWlt9rbyDn92a1DqWOw9vWG2MFoays0sgObmWazO5BQPiFucnnEAjpAB+/Sw==" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.2.5/jquery.fancybox.min.css" integrity="sha256-ygkqlh3CYSUri3LhQxzdcm0n1EQvH2Y+U5S2idbLtxs=" crossorigin="anonymous">
  
  
  
  
  <link rel="stylesheet" href="//fonts.googleapis.com/css?family=Montserrat:400,700%7cRoboto:400,400italic,700%7cRoboto&#43;Mono">
  
  <link rel="stylesheet" href="/styles.css">
  
  <link rel="stylesheet" href="/css/custom.css">
  

  
    <script>
      window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)};ga.l=+new Date;
      ga('create', 'UA-84019592-2', 'auto');
      
      ga('require', 'eventTracker');
      ga('require', 'outboundLinkTracker');
      ga('require', 'urlChangeTracker');
      ga('send', 'pageview');
    </script>
    <script async src="//www.google-analytics.com/analytics.js"></script>
    
    <script async src="https://cdnjs.cloudflare.com/ajax/libs/autotrack/2.4.1/autotrack.js" integrity="sha512-HUmooslVKj4m6OBu0OgzjXXr+QuFYy/k7eLI5jdeEy/F4RSgMn6XRWRGkFi5IFaFgy7uFTkegp3Z0XnJf3Jq+g==" crossorigin="anonymous"></script>
    
  

  
  <link rel="alternate" href="/index.xml" type="application/rss+xml" title="DNA confesses and Data speak">
  <link rel="feed" href="/index.xml" type="application/rss+xml" title="DNA confesses and Data speak">
  

  <link rel="manifest" href="/site.webmanifest">
  <link rel="icon" type="image/png" href="/img/icon.png">
  <link rel="apple-touch-icon" type="image/png" href="/img/icon-192.png">

  <link rel="canonical" href="/publication/2017-02-15-ifn-signaling-tumor-pd1-resistance/">

  <meta property="twitter:card" content="summary_large_image">
  
  <meta property="twitter:site" content="@https://twitter.com/tangming2005">
  <meta property="twitter:creator" content="@https://twitter.com/tangming2005">
  
  <meta property="og:site_name" content="DNA confesses and Data speak">
  <meta property="og:url" content="/publication/2017-02-15-ifn-signaling-tumor-pd1-resistance/">
  <meta property="og:title" content="Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy | DNA confesses and Data speak">
  <meta property="og:description" content="Immune checkpoint therapies exhibit impressive efficacy in some patients with melanoma or lung cancer, but the lack of response in most cases presses the question of how general efficacy can be improved. In addressing this question, we generated a preclinical tumor model to study anti-PD-1 resistance by in vivo passaging of Kras-mutated, p53-deficient murine lung cancer cells (p53R172HDg/Ã¾K-rasLA1/Ã¾) in a syngeneic host exposed to repetitive dosing with anti-mouse PD-1 antibodies. PD-L1 (CD274) expression did not differ between the resistant and parental tumor cells. However, the expression of important molecules in the antigen presentation pathway, including MHC class I and II, as well as b2-microglobulin, were significantly downregulated in the anti-PD-1â€“resistant tumors compared with parental tumors. Resistant tumors also contained fewer CD8Ã¾ (CD8a) and CD4Ã¾ tumor-infiltrating lymphocytes and reduced production of IFNg. Localized radiotherapy induced IFNb production, thereby elevating MHC class I expression on both parental and resistant tumor cells and restoring the responsiveness of resistant tumors to anti-PD-1 therapy. Conversely, blockade of type I IFN signaling abolished the effect of radiosensitization in this setting. Collectively, these results identify a mechanism of PD-1 resistance and demonstrate that adjuvant radiotherapy can overcome resistance. These findings have immediate clinical implications for extending the efficacy of anti-PD-1 immune checkpoint therapy in patients."><meta property="og:image" content="/img/headers/anti-PD1.png">
  <meta property="og:locale" content="en-us">
  
  <meta property="article:published_time" content="2017-02-15T00:00:00-06:00">
  
  <meta property="article:modified_time" content="2017-02-15T00:00:00-06:00">
  

  
  

  <title>Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy | DNA confesses and Data speak</title>

</head>
<body id="top" data-spy="scroll" data-target="#toc" data-offset="71" >

<nav class="navbar navbar-default navbar-fixed-top" id="navbar-main">
  <div class="container">

    
    <div class="navbar-header">
      
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse"
              data-target=".navbar-collapse" aria-expanded="false">
        <span class="sr-only">Toggle navigation</span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      
      <a class="navbar-brand" href="/">DNA confesses and Data speak</a>
    </div>

    
    <div class="collapse navbar-collapse">

      
      
      <ul class="nav navbar-nav navbar-right">
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#about">
            
            <span>Home</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#publications">
            
            <span>Publications</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#posts">
            
            <span>Posts</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#projects">
            
            <span>Projects</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#talks">
            
            <span>Talks &amp; Teachings</span>
            
          </a>
        </li>

        
        

        
        
        
        
        

        <li class="nav-item">
          <a href="/#cv">
            
            <span>CV</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#contact">
            
            <span>Contact</span>
            
          </a>
        </li>

        
        
      

      
      </ul>

    </div>
  </div>
</nav>

<div class="pub" itemscope itemtype="http://schema.org/CreativeWork">

  
<div class="article-header">
  
  
    <img src="/img/headers/anti-PD1.png" class="article-banner" itemprop="image">
  

  <span class="article-header-caption">My caption ðŸ˜„</span>
</div>



  <div class="article-container">
    <h1 itemprop="name">Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy</h1>
    <span class="pub-authors" itemprop="author">
      
      Xiaohong Wang, &hellip;, Ming Tang et.al
      
    </span>
    <span class="pull-right">
      
<div class="share-box" aria-hidden="true">
  <ul class="share">
    <li>
      <a class="twitter"
         href="https://twitter.com/intent/tweet?text=Suppression%20of%20Type%20I%20IFN%20Signaling%20in%20Tumors%20Mediates%20Resistance%20to%20Anti-PD-1%20Treatment%20That%20Can%20Be%20Overcome%20by%20Radiotherapy&amp;url=%2fpublication%2f2017-02-15-ifn-signaling-tumor-pd1-resistance%2f"
         target="_blank" rel="noopener">
        <i class="fa fa-twitter"></i>
      </a>
    </li>
    <li>
      <a class="facebook"
         href="https://www.facebook.com/sharer.php?u=%2fpublication%2f2017-02-15-ifn-signaling-tumor-pd1-resistance%2f"
         target="_blank" rel="noopener">
        <i class="fa fa-facebook"></i>
      </a>
    </li>
    <li>
      <a class="linkedin"
         href="https://www.linkedin.com/shareArticle?mini=true&amp;url=%2fpublication%2f2017-02-15-ifn-signaling-tumor-pd1-resistance%2f&amp;title=Suppression%20of%20Type%20I%20IFN%20Signaling%20in%20Tumors%20Mediates%20Resistance%20to%20Anti-PD-1%20Treatment%20That%20Can%20Be%20Overcome%20by%20Radiotherapy"
         target="_blank" rel="noopener">
        <i class="fa fa-linkedin"></i>
      </a>
    </li>
    <li>
      <a class="weibo"
         href="http://service.weibo.com/share/share.php?url=%2fpublication%2f2017-02-15-ifn-signaling-tumor-pd1-resistance%2f&amp;title=Suppression%20of%20Type%20I%20IFN%20Signaling%20in%20Tumors%20Mediates%20Resistance%20to%20Anti-PD-1%20Treatment%20That%20Can%20Be%20Overcome%20by%20Radiotherapy"
         target="_blank" rel="noopener">
        <i class="fa fa-weibo"></i>
      </a>
    </li>
    <li>
      <a class="email"
         href="mailto:?subject=Suppression%20of%20Type%20I%20IFN%20Signaling%20in%20Tumors%20Mediates%20Resistance%20to%20Anti-PD-1%20Treatment%20That%20Can%20Be%20Overcome%20by%20Radiotherapy&amp;body=%2fpublication%2f2017-02-15-ifn-signaling-tumor-pd1-resistance%2f">
        <i class="fa fa-envelope"></i>
      </a>
    </li>
  </ul>
</div>


    </span>

    

    
    <h3>Abstract</h3>
    <p class="pub-abstract" itemprop="text">Immune checkpoint therapies exhibit impressive efficacy in some patients with melanoma or lung cancer, but the lack of response in most cases presses the question of how general efficacy can be improved. In addressing this question, we generated a preclinical tumor model to study anti-PD-1 resistance by in vivo passaging of Kras-mutated, p53-deficient murine lung cancer cells (p53R172HDg/Ã¾K-rasLA1/Ã¾) in a syngeneic host exposed to repetitive dosing with anti-mouse PD-1 antibodies. PD-L1 (CD274) expression did not differ between the resistant and parental tumor cells. However, the expression of important molecules in the antigen presentation pathway, including MHC class I and II, as well as b2-microglobulin, were significantly downregulated in the anti-PD-1â€“resistant tumors compared with parental tumors. Resistant tumors also contained fewer CD8Ã¾ (CD8a) and CD4Ã¾ tumor-infiltrating lymphocytes and reduced production of IFNg. Localized radiotherapy induced IFNb production, thereby elevating MHC class I expression on both parental and resistant tumor cells and restoring the responsiveness of resistant tumors to anti-PD-1 therapy. Conversely, blockade of type I IFN signaling abolished the effect of radiosensitization in this setting. Collectively, these results identify a mechanism of PD-1 resistance and demonstrate that adjuvant radiotherapy can overcome resistance. These findings have immediate clinical implications for extending the efficacy of anti-PD-1 immune checkpoint therapy in patients.</p>
    

    
    <div class="row">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading">Type</div>
          <div class="col-xs-12 col-sm-9">
            
            <a href="/publication/#2">
              Journal article
            </a>
            
          </div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>
    

    
    <div class="row">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading">Publication</div>
          <div class="col-xs-12 col-sm-9">In <em>Cancer Research</em>, Cancer Research.</div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>
    

    <div class="row">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading">Date</div>
          <div class="col-xs-12 col-sm-9" itemprop="datePublished">
            February, 2017
          </div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>

    <div class="row" style="padding-top: 10px">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading" style="line-height:34px;">Links</div>
          <div class="col-xs-12 col-sm-9">

            




<a class="btn btn-primary btn-outline" href="/files/papers/Uveal.pdf" target="_blank" rel="noopener">
  PDF
</a>
















          </div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>

    <div class="space-below"></div>

    <div class="article-style"><p>More detail can easily be written here using <em>Markdown</em> and $\rm \LaTeX$ math code.</p>
</div>

    


  </div>
</div>



<footer class="site-footer">
  <div class="container">
    <p class="powered-by">

      &copy; 2018 Ming Tang &middot; 

      Powered by the
      <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
      <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

      <span class="pull-right" aria-hidden="true">
        <a href="#" id="back_to_top">
          <span class="button_icon">
            <i class="fa fa-chevron-up fa-2x"></i>
          </span>
        </a>
      </span>

    </p>
  </div>
</footer>


<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <button type="button" class="close btn-large" data-dismiss="modal">&times;</button>
        <h4 class="modal-title">Cite</h4>
      </div>
      <div>
        <pre><code class="modal-body tex"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-primary btn-outline js-copy-cite" href="#" target="_blank">
          <i class="fa fa-copy"></i> Copy
        </a>
        <a class="btn btn-primary btn-outline js-download-cite" href="#" target="_blank">
          <i class="fa fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

    

    
    

    

    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.2.1/jquery.min.js" integrity="sha512-3P8rXCuGJdNZOnUx/03c1jOTnMn3rP63nBip5gOP2qmUh5YAdVAvFZ1E+QLZZbC1rtMrQb+mah3AfYW11RUrWA==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.3/imagesloaded.pkgd.min.js" integrity="sha512-umsR78NN0D23AzgoZ11K7raBD+R6hqKojyBZs1w8WvYlsI+QuKRGBx3LFCwhatzBunCjDuJpDHwxD13sLMbpRA==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.3.7/js/bootstrap.min.js" integrity="sha512-iztkobsvnjKfAtTNdHkGVjAYTrrtlC7mGp/54c40wowO7LhURYl3gVzzcEqGl/qKXQltJ2HwMrdLcNUdo+N/RQ==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.4/isotope.pkgd.min.js" integrity="sha512-VDBOIlDbuC4VWxGJNmuFRQ0Li0SKkDpmGyuhAG5LTDLd/dJ/S0WMVxriR2Y+CyPL5gzjpN4f/6iqWVBJlht0tQ==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.2.5/jquery.fancybox.min.js" integrity="sha256-X5PoE3KU5l+JcX+w09p/wHl9AzK333C4hJ2I9S5mD4M=" crossorigin="anonymous"></script>
    
    
    <script src="/js/hugo-academic.js"></script>
    

    
    
      
      
      <script src="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/highlight.min.js" integrity="sha256-/BfiIkHlHoVihZdc6TFuj7MmJ0TWcWsMXkeDFwhi0zw=" crossorigin="anonymous"></script>
      

      
      <script src="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/languages/go.min.js"></script>
      
      <script src="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/languages/bash.min.js"></script>
      
      <script src="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/languages/shell.min.js"></script>
      
      <script src="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/languages/python.min.js"></script>
      
      <script src="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/languages/R.min.js"></script>
      

      

      <script>hljs.initHighlightingOnLoad();</script>
    

    
    
    <script type="text/x-mathjax-config">
        MathJax.Hub.Config({ tex2jax: { inlineMath: [['$','$'], ['\\(','\\)']] } });
    </script>
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS_CHTML" integrity="sha512-tOav5w1OjvsSJzePRtt2uQPFwBoHt1VZcUq8l8nm5284LEKE9FSJBQryzMBzHxY5P0zRdNqEcpLIRVYFNgu1jw==" crossorigin="anonymous"></script>
    
    

  </body>
</html>

